GridAI Technologies Corp. News Releases

GridAI Technologies Corp. Announces Receipt of NASDAQ Notice Regarding Late Form 10-K Filing

Tue, 28 Apr 2026 17:20:00 -0400

Boca Raton, Florida--(Newsfile Corp. - April 28, 2026) - GridAI Technologies Corp. (NASDAQ: GRDX) (the "Company") today announced that On April 22, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the filing of periodic financial reports requirement for continued listing on The Nasdaq Capital Market, under Listing Rule 5250(c)(1), because the Company has not yet filed...

ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand

Wed, 01 Oct 2025 08:30:00 -0400

Transaction positions ENTO in the high-growth AI energy-infrastructure market, amid a surge of multi-billion-dollar hyperscaler spending on data centers, and rapid growth in behind-the-meter energy storage solutions Boca Raton, Florida--(Newsfile Corp. - October 1, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("ENTO" or the "Company") today announced it has acquired 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and device platform that enables utilities, retailers, and...

Entero Therapeutics, Inc. Announces Reverse Stock Split

Thu, 14 Aug 2025 09:15:00 -0400

Boca Raton, Florida--(Newsfile Corp. - August 14, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced that, it will effect a 1 for 3 reverse stock split of its common stock. The Company expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on August...

Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules

Mon, 11 Aug 2025 07:30:00 -0400

Boca Raton, Florida--(Newsfile Corp. - August 11, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) (the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of approximately $3 million of pre-funded and common warrants. The entire transaction has been priced at the market...

Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC

Mon, 24 Mar 2025 22:51:00 -0400

Boca Raton, Florida--(Newsfile Corp. - March 24, 2025) - Entero Therapeutics, Inc. (NASDAQ: ENTO) ("Entero" or the "Company"), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, announced today that Entero has successfully negotiated and signed a rescission agreement (the "Rescission Agreement") with 100% of the previous shareholders of ImmunogenX, LLC ("IMGX") in relation to the ImmunogenX Business...